Zydol SR 50mg
*Company:
Grunenthal Pharma Ltd.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 20 September 2024
File name
ie_uk-leaflet-zydol-sr50mg-tablets-v4-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - how to take/use
- Change to section 5 - how to store or dispose
Updated on 20 September 2024
File name
ie-spc-2242-5-6-sr50mg-tabs-v17-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 31 May 2024
File name
ie_uk-leaflet-zydol-sr50mg-tablets-v4-clean IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - how to take/use
- Change to section 5 - how to store or dispose
Free text change information supplied by the pharmaceutical company
Do and tell Type IA(IN) variation change that was implemented on 31st May 2024. PSUSA outcome PSUSA/00003002/202306
Updated on 31 May 2024
File name
ie-spc-2242-5-6-sr50mg-tabs-v17-clean IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Do and tell Type IA(IN) variation change that was implemented on 31st May 2024. PSUSA outcome PSUSA/00003002/202306
Updated on 11 January 2024
File name
ie_uk-leaflet-zydol-sr50mg-tablets-v3.0 ipha.pdf
Reasons for updating
- Change to further information section
- Change to date of revision
Updated on 31 January 2023
File name
ie-spc-2242-5-6-sr50mg-tabs-v16-ipha clean.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 February 2022
File name
ie-spc-2242-5-6-sr50mg-tabs-v16-ipha clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Approval of End of Procedure of two work-sharing procedures as outlined below;
- DE/H/XXXX/WS/964 - Grouped Type II and Type IB variations.
Change 1: Type II - to update product information following CCDS update with additions of 3 ADRs and working adaptation of section 5.3 (pre-clinical safety data) with impact on the wording in section 4.6 (fertility).
Change 2: Type IB unforseen - to implementation PSUSA/00003002/202005 outcome.
- DE/H/xxxx/WS/1000 – Type IB PRAC change - to implement the PRAC change recommendation on signals based on EMA/PRAC/2050777/2021; EPITT no 19635 (dated 31st May 2021) into the product information (SmPC and PIL).
Updated on 21 February 2022
File name
ie-spc-2242-5-6-sr50mg-tabs-v16-ipha clean.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Approval of End of Procedure of two work-sharing procedures as outlined below;
- DE/H/XXXX/WS/964 - Grouped Type II and Type IB variations.
Change 1: Type II - to update product information following CCDS update with additions of 3 ADRs and working adaptation of section 5.3 (pre-clinical safety data) with impact on the wording in section 4.6 (fertility).
Change 2: Type IB unforseen - to implementation PSUSA/00003002/202005 outcome.
- DE/H/xxxx/WS/1000 – Type IB PRAC change - to implement the PRAC change recommendation on signals based on EMA/PRAC/2050777/2021; EPITT no 19635 (dated 31st May 2021) into the product information (SmPC and PIL).
Updated on 07 February 2022
File name
ie_uk-leaflet-zydol-sr50mg-pr-tablets-v2.0 ipha.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Individual PILs superseded by joint PIL
Free text change information supplied by the pharmaceutical company
Joint PIL for Ireland and UK has been approved by both HPRA and MHRA. The 2 safety changes that have been approved in the 2 worksharing procedures DE/H/xxxx/964 and 1000 are also updated in this joint PIL approval impacting warnings and precautions and possible side effects.
Updated on 09 March 2020
File name
m1-3-1-leaflet-2242-5-6-sr50mg-tablets-v12-ipha.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
Information added on sleep related breathing disorders
Updated on 09 March 2020
File name
ie-spc-2242-5-6-sr50mg-tabs-v11-ipha.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Information added on sleep-related breathing disorders
Updated on 25 February 2019
File name
m1-3-1-leaflet-2242-5-6-sr50mg-tablets-v11-ipha.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 25 February 2019
File name
ie-spc-2242-5-6-sr50mg-tabs-v10-ipha.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
m1-3-1-leaflet-2242-5-6-sr50mg-tablets-v10-no-header.pdf
Updated on 29 May 2018
File name
ie-spc-2242-5-6-sr50mg-tabs-v9-ipha.docx
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Update to marketing authorisation holder and PA number
Updated on 25 May 2018
File name
ie-spc-1189-1-9-sr50mg-tabs-v8-clean.docx
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.4
- Updated text on dependence and treatment discontinuation
- Text added on CYP2D6 metabolism
- Text added on available information on the use in post-operative children
- Text added on the use in children with compromised respiratory function
Section 4.6
- Update to breast-feeding section
Section 4.8
- Update on how to report adverse events to the MHRA
Section 5.2
- Deleted ’Up to now, clinically relevant interactions have not been reported'
Section 7 : MA holder changed to Grunenthal Pharma Ltd
Section 8: MA number changed to PA 2242/5/6
Section 10: Date of revision as 01 May 2018
Updated on 18 May 2018
File name
m1-3-1-leaflet-2242-5-6-sr50mg-tablets-v10-no-header.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Updated on 10 May 2018
File name
m1-3-1-leaflet-1189-1-9-sr50mg-tablets-v9-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 19 October 2016
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 19 October 2016
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 Posology and method of administration:
Reference to section 5.1 included
Section 5.1 Pharmacodynamic properties:
Information about paediatric population added
Section 5.2 Pharmacokinetic properties:
Information about paediatric population added
Updated on 21 July 2015
File name
PIL_14473_722.pdf
Reasons for updating
- New PIL for new product
Updated on 21 July 2015
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Details of adverse event reporting changed from IMB to HPRA.
Updated on 21 July 2015
Reasons for updating
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 04 February 2014
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 - formatting changes
Section 4.8 - addition of hypoglycaemia is a side effect with unknown frequency
- reporting of side effect
Section 10 - September 2013
Updated on 04 February 2014
Reasons for updating
- Change to side-effects
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 12 September 2013
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Editorial changes to sections 1,2, 4.2, 4.3, 4.4, 4.7, 4.9, 5.2, 5.3, 6.1, 6.3, 6.6, 10.
- Section 4.5
o Added information on Serotonin-norepinehphrine reuptake inhibitors (SNRIs) induced convulsions can be increased by tramadol.
o Added Symptoms/signs of serotonin syndrome
- Section 4.6
o Statement on fertility included
- Section 4.8
o Included adverse reaction relating to : Immune system disorders, investigations, vascular disorders, metabolism disorders
o Updates to adverse reactions relating to: cardiac disorders, nervous system disorders, psychiatric disorders, Eye disorders, respiratory, thoracic and mediastinal disorders, gastro intestinal disorders, skin disorders, hepatobiliary disorders, renal disorders and general disorders
Updated on 06 September 2013
Reasons for updating
- Change of contraindications
- Change to side-effects
- Change to date of revision
- Improved electronic presentation
Updated on 19 July 2011
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 4.8 - Undesirable effects
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8, ',' have been removed in the frequencies and replaced with 'to' (format change).
Section 9, the 'Date of last renewal' has been added.
Section 10, the 'Date of revision of the text' has been updated as per the issued PA Schedule.
Updated on 15 July 2011
Reasons for updating
- Change to improve clarity and readability
Updated on 15 July 2011
Reasons for updating
- Improved electronic presentation
Updated on 10 June 2010
Reasons for updating
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change to information about pregnancy or lactation
- Change to information about driving or using machinery
- Change to further information section
- Change to appearance of the medicine
- Change to dosage and administration
Updated on 09 June 2010
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
SPC section 4.9 Overdose, has been updated to include information about gastrointestinal decontamination with activated charcoal.
Updated on 06 November 2009
Reasons for updating
- New PIL for medicines.ie
Updated on 31 October 2007
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)